IP Library › Granted Patent US 7,858,640

Granted Patent B2

US 7,858,640 · App. 12/066,603 · Granted Dec 28, 2010

Quinolines and their therapeutic use

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,858,640
App. No.: 12/066,603
Granted: Dec 28, 2010
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Compounds of formula [1] are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory components; in which: R 1 -R 9 are various substituents; A is —CHR 10 —, —C(O)—, —S(O)n—, —O—, or —NR 10 — wherein n is an integer from 0-1 and R 10 is selected from various substituents; B is a direct bond or a divalent radical; R 11 and R 12 are selected from cvarious substituents; X is a carboxylic acid, tetrazole, 3-hydroxyisoxazole, hydroxamic acid, phosphinate, phosphonate, phosphonamide, sulfonic acid group, or a group of formula C═(O)NHSO 2 R 6 or SO 2 NHC(═O)R 6 ; and Y is aryl, heteroaryl, aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl group.

Claims (87)

1. A compound of formula [1] or a pharmaceutically acceptable salt or N-oxide thereof:

in which:

R 1 is hydrogen, C 1 -C 6 alkyl, fully or partially fluorinated C 1 -C 6 alkyl, cyclopropyl, halo, —S(O) n R 6 , —SO 2 NR 7 R 8 , —NR 7 R 8 , —NR 7 C(O)R 6 , —CO 2 R 7 , —C(O)NR 7 R 8 , —C(O)R 6 , —NO 2 , or —CN;

R 2 , R 3 , R 4 and R 5 are independently hydrogen, C 1 -C 6 alkyl, fully or partially fluorinated C 1 -C 6 alkyl, cyclopropyl, halo, —S(O) n R 6 , —SO 2 NR 7 R 8 , —NR 7 R 8 , —NR 7 C(O)R 6 , —CO 2 R 7 , —C(O)NR 7 R 8 , —C(O)R 6 , —NO 2 , or —CN or a group —OR 9 ;

wherein each R 6 is independently C 1 -C 6 alkyl, fully or partially fluorinated C 1 -C 6 alkyl, cycloalkyl, aryl, or heteroaryl;

R 7 , R 8 are independently C 1 -C 6 alkyl, fully or partially fluorinated C 1 -C 6 alkyl, cycloalkyl, cycloalkyl-(C 1 -C 6 alkyl)-, aryl, heteroaryl or hydrogen;

R 9 is C 1 -C 6 alkyl, fully or partially fluorinated C 1 -C 6 alkyl, cycloalkyl, cycloalkyl-(C 1 -C 6 alkyl)-, or a group —SO 2 R 6 ;

A is —CHR 10 —, —C(O)—, —S(O) n —, —O—, or —NR 10 — wherein n is an integer from 0-2 and R 10 is hydrogen, C 1 -C 3 alkyl, or fully or partially fluorinated C 1 -C 3 alkyl group;

B is a divalent radical selected from —CH 2 —, —CH 2 CH 2 —, —CHR 11 —, —CR 11 R 12 —, —CH 2 CHR 11 — in either orientation, —CH 2 CR 11 R 12 — in either orientation, —OCH(CH 3 )— or —OCH 2 — wherein the oxygen is attached to the ring carrying R 1 , R 2 and R 3 ;

—CHR 11 CHR 12 — in either orientation, and —(CR 11 R 12 ) p —Z— wherein Z is attached to the ring carrying R 1 , R 2 and R 3 ; wherein

R 11 is C 1 -C 3 alkyl, cyclopropyl, or fully or partially fluorinated C 1 -C 3 alkyl;

R 12 is methyl or fully or partially fluorinated methyl;

p is independently 1 or 2; and

Z is —O—, —NH—, or —S(O) n —, wherein n is an integer from 0-2;

X is a carboxylic acid, tetrazole, 3-hydroxyisoxazole, hydroxamic acid, phosphinate, phosphonate, phosphonamide, or sulfonic acid group, or a group of formula C(═O)NHSO 2 R 6 or SO 2 NHC(═O)R 6 ; and

Y is aryl, heteroaryl, aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl group;

wherein R 4 and R 5 are not simultaneously hydrogen.

2. The compound as claimed in claim 1 , wherein R 1 is fluoro or chloro; R 2 and R 3 are hydrogen; R 4 is methyl, ethyl, methoxy or difluoromethoxy; R 5 is methyl, ethyl, ethoxy, isopropoxy, difluoromethoxy or cyano; A is —CH 2 —, —O— or —S(O) n — wherein n is 0, 1 or 2; B is —CH 2 —, —OCH(CH 3 )— or —OCH 2 — wherein the oxygen is attached to the ring carrying R 1 , R 2 and R 3 ; X is —CO 2 H; and Y is 4-fluorophenyl, 4-chlorophenyl, 4-methanesulfonylphenyl, 4-ethanesulfonylphenyl, 4-(morpholine-4-sulfonyl)phenyl, 4-(pyrrolidine-1-carbonyl)phenyl, 2,4-difluorophenyl, 2,4-dichlorophenyl, 2-chloro-2-fluorophenyl, 2-chloro-4-fluorophenyl, 2-chloro-4-methanesulfonylphenyl, 2-chloro-4-(pyrrolidine-1-carbonyl)phenyl or 2-chloro-4-cyclobutylcarbamoyl.

3. A compound selected from the group consisting of:

[8-chloro-3-(4-chlorobenzyl)-4-difluoromethoxy-2-ethylquinolin-5-yloxy]acetic acid,

[3-(4-chlorobenzyl)-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy]acetic acid,

[3-(2,4-dichlorobenzyl)-2-difluoromethoxy-8-fluoro-4-methylquinolin-5-yloxy]acetic acid,

[4-difluoromethoxy-2-ethyl-8-fluoro-3-(4-fluorobenzyl)quinolin-5-yloxy]acetic acid,

[3-(2,4-difluorobenzyl)-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy]acetic acid,

[3-(2,4-dichlorobenzyl)-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy]acetic acid,

[3-(4-chloro-2-fluorobenzyl)-2-difluoromethoxy-8-fluoro-4-methylquinolin-5-yloxy]acetic acid,

[8-chloro-3-(4-chlorobenzyl)-2-difluoromethoxy-4-methylquinolin-5-yloxy]acetic acid,

[3-(2-chloro-4-fluorobenzyl)-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy]acetic acid,

[3-(2-chloro-4-fluorobenzyl)-2-difluoromethoxy-8-fluoro-4-methylquinolin-5-yloxy]acetic acid,

[8-chloro-3-(4-chloro-2-fluorobenzyl)-4-difluoromethoxy-2-ethylquinolin-5-yloxy]acetic acid,

[3-(4-chloro-2-fluorobenzyl)-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy]acetic acid,

{4-difluoromethoxy-2-ethyl-8-fluoro-3-[4-(morpholine-4-sulfonyl)benzyl]quinolin-5-yloxy}acetic acid,

{4-difluoromethoxy-2-ethyl-8-fluoro-3-[4-(pyrrolidine-1-carbonyl)benzyl]quinolin-5-yloxy}acetic acid,

2-[3-(2,4-dichlorobenzyl)-2-difluoromethoxy-8-fluoro-4-methylquinolin-5-yloxy]propionic acid,

(S)-2-[3-(2,4-dichlorobenzyl)-2-difluoromethoxy-8-fluoro-4-methylquinolin-5-yloxy]propionic acid,

2-[8-chloro-3-(4-chlorobenzyl)-2-difluoromethoxy-4-methylquinolin-5-yloxy]propionic acid,

{8-chloro-4-difluoromethoxy-2-ethyl-3-[4-(pyrrolidine-1-carbonyl)benzyl]-quinolin-5-yloxy}acetic acid,

{3-[2-chloro-4-(pyrrolidine-1-carbonyl)benzyl]-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy}acetic acid,

(S)-2-{3-[2-chloro-4-(pyrrolidine-1-carbonyl)benzyl]-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy}propionic acid,

(S)-2-[3-(2,4-dichlorobenzyl)-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy]propionic acid,

[3-(2-chloro-4-cyclobutylcarbamoylbenzyl)-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy]acetic acid; and

(S)-2-[3-(2-chloro-4-cyclobutylcarbamoylbenzyl)-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy]propionic acid;

and pharmaceutically acceptable salts or N-oxides thereof.

4. The compound as claimed in claim 1 , wherein R 1 is Cl, R 2 and R 3 are H, R 4 is difluoromethoxy, R 5 is ethyl, A is —CH 2 —, B is —O—CH 2 —, X is carboxylic acid and Y is 4-chlorophenyl.

5. A pharmaceutical composition comprising

i) a compound of formula [1] or a pharmaceutically acceptable salt or N-oxide thereof: